The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study

Table 3 Analyses of TFV-DP, FTC-TP and EFV combination studies in the HIV-1 RT enzymatic assay^a.

Analysis Methods	Drug Combinations
	TFV-DP+FTC-TP	TFV-DP+EFV	FTC-TP+EFV
Median-effect (CI value)	synergy^a (0.47 ± 0.09)	moderate synergy (0.75 ± 0.04)	moderate synergy (0.70 ± 0.03)
MacSynergy II^b (synergy/antagonism volume)	additive (0.63 ± 1.2/-2.7 ± 3.4)	minor synergy (44 ± 20/0 ± 0)	minor synergy (41 ± 15/-0.5 ± 1.1)
Isobologram (ADA^c, p value)	synergy (-0.43, 0.001)	synergy (-0.20, 0.001)	synergy (-0.14, 0.002)
Berenbaum Combination Indices	synergy	ND^d	ND
Yonetani-Theorell Plots	synergy	synergy	synergy

^a Definition for degree of synergy (whenever applicable) is described in Methods.
^b The volumes are calculated at the 95% confidence interval. The values are averages from 3 to 4 independent measurements. Five parallel repeats were tested in each measurement.
^c ADA = average deviation from additivity
^d ND = not determined.

ISSN: 1742-4690